FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015016837> ?p ?o ?g. }

• W2015016837 endingPage "786" @default.
• W2015016837 startingPage "780" @default.
• W2015016837 abstract "Objective.—To compare the efficacy of a single over‐the‐counter dose (7.5 mg/kg, p.o.) of children's ibuprofen suspension vs. placebo for the acute treatment of pediatric migraine. Background.—Migraine occurs in 4% of young children. There is a paucity of controlled clinical research in the treatment of childhood migraine and there are currently no approved drugs in the USA for treatment of migraine in children 12 years of age. The purpose of this study is to assess the efficacy and tolerability of a single OTC dose of ibuprofen suspension for the acute treatment of childhood migraine. Methods.—Prospective, double‐blind, placebo‐controlled, parallel group, randomized study of children 6‐12 yrs with migraine (I.H.S.‐R1997) treating 1 attack with a 7.5 mg/kg liq. ibuprofen vs matching placebo. Efficacy measures: (1) Headache severity based upon a 4 pt scale (severe, mod., mild, no headache) at 30, 60, 90, 120, 180 and 240 minutes post dose, and (2) nausea, vomiting, and photo/phonophobia at 120 min. The 1° endpoint was cumulative % of responders (severe or mod. headache reduced to mild or none) by 120 minutes. Secondary endpoints were headache recurrence within 4‐24 hours and need for rescue medicines within 4 hours. Results.—138 enrolled; 84 treated/completed diary. 45 active agent, 39 placebo. The 2 groups were comparable (active: placebo) ‐ Ages: 9: 9.1, gender boy/girl ‐ 1.25: 1.6, and diagnosis: migraine w/o aura ‐ 86%: 79%. Concomitant use of prophylactic Rx: 24%: 10% (Table 3) . Endpoint Ibuprofen (N=45) Placebo (N=39) P ‐value Cum. % responders, 2 hr (1° endpoint) 76% 53% 0.006 2 pt. improvement in severity, 2 hr 27 (62%) 11 (28%) 0.004 Median pain score at 2 hr 2 3 <0.02 Headache recurrence (within 4‐24 hr) 8 (18%) 14 (36%) 0.06 Need for rescue medication 1 (2%) 15 (38%) <0.001 Nausea was eliminated in 60% of the ibuprofen treated patients and 39% of the placebo group (p<0.001). Vomiting, photophobia and phonophobia had marginal, but not statistically significant, decreases at 2 hours. A striking gender difference was noted (Table 4) : Endpoint Ibuprofen Placebo P ‐value Cum. % responders 76% 53% 0.006 BOYS 84% 43.4 <0.0006 GIRLS 65% 66.7 0.8 Headache recurrence 5 13 <0.005 BOYS 0 8 <0.001 GIRLS 5 5 NS No AE's were reported. Conclusion.—Children's ibuprofen suspension at an OTC dose of 7.5 mg/kg is an effective and well‐tolerated agent for pain relief in the acute treatment of childhood migraine, particularly in boys. There is a striking difference in gender response rates and placebo responder rates between girls and boys. The boys responded at a statistically significant rate, and girls failed to do so because of a very high placebo responder rate. Multi‐center trials are recommended." @default.
• W2015016837 created "2016-06-24" @default.
• W2015016837 creator A5005316951 @default.
• W2015016837 creator A5005673236 @default.
• W2015016837 creator A5019206487 @default.
• W2015016837 creator A5020776221 @default.
• W2015016837 creator A5022759927 @default.
• W2015016837 creator A5033294811 @default.
• W2015016837 creator A5059903481 @default.
• W2015016837 creator A5079147180 @default.
• W2015016837 creator A5086077254 @default.
• W2015016837 date "2002-09-01" @default.
• W2015016837 modified "2023-10-18" @default.
• W2015016837 title "Children's Ibuprofen Suspension for the Acute Treatment of Pediatric Migraine" @default.
• W2015016837 cites W1993529543 @default.
• W2015016837 cites W2020882008 @default.
• W2015016837 cites W2021282404 @default.
• W2015016837 cites W2026186430 @default.
• W2015016837 cites W2067351273 @default.
• W2015016837 cites W2089787171 @default.
• W2015016837 cites W2143365051 @default.
• W2015016837 doi "https://doi.org/10.1046/j.1526-4610.2002.02180.x" @default.
• W2015016837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12390641" @default.
• W2015016837 hasPublicationYear "2002" @default.
• W2015016837 type Work @default.
• W2015016837 sameAs 2015016837 @default.
• W2015016837 citedByCount "165" @default.
• W2015016837 countsByYear W20150168372012 @default.
• W2015016837 countsByYear W20150168372013 @default.
• W2015016837 countsByYear W20150168372014 @default.
• W2015016837 countsByYear W20150168372015 @default.
• W2015016837 countsByYear W20150168372016 @default.
• W2015016837 countsByYear W20150168372017 @default.
• W2015016837 countsByYear W20150168372018 @default.
• W2015016837 countsByYear W20150168372019 @default.
• W2015016837 countsByYear W20150168372020 @default.
• W2015016837 countsByYear W20150168372021 @default.
• W2015016837 countsByYear W20150168372022 @default.
• W2015016837 countsByYear W20150168372023 @default.
• W2015016837 crossrefType "journal-article" @default.
• W2015016837 hasAuthorship W2015016837A5005316951 @default.
• W2015016837 hasAuthorship W2015016837A5005673236 @default.
• W2015016837 hasAuthorship W2015016837A5019206487 @default.
• W2015016837 hasAuthorship W2015016837A5020776221 @default.
• W2015016837 hasAuthorship W2015016837A5022759927 @default.
• W2015016837 hasAuthorship W2015016837A5033294811 @default.
• W2015016837 hasAuthorship W2015016837A5059903481 @default.
• W2015016837 hasAuthorship W2015016837A5079147180 @default.
• W2015016837 hasAuthorship W2015016837A5086077254 @default.
• W2015016837 hasConcept C126322002 @default.
• W2015016837 hasConcept C141071460 @default.
• W2015016837 hasConcept C142724271 @default.
• W2015016837 hasConcept C187212893 @default.
• W2015016837 hasConcept C197934379 @default.
• W2015016837 hasConcept C204787440 @default.
• W2015016837 hasConcept C27081682 @default.
• W2015016837 hasConcept C2777350023 @default.
• W2015016837 hasConcept C2778375690 @default.
• W2015016837 hasConcept C2778541695 @default.
• W2015016837 hasConcept C2779631551 @default.
• W2015016837 hasConcept C2779944601 @default.
• W2015016837 hasConcept C2780580376 @default.
• W2015016837 hasConcept C2780590625 @default.
• W2015016837 hasConcept C2780852908 @default.
• W2015016837 hasConcept C42219234 @default.
• W2015016837 hasConcept C71924100 @default.
• W2015016837 hasConcept C98274493 @default.
• W2015016837 hasConceptScore W2015016837C126322002 @default.
• W2015016837 hasConceptScore W2015016837C141071460 @default.
• W2015016837 hasConceptScore W2015016837C142724271 @default.
• W2015016837 hasConceptScore W2015016837C187212893 @default.
• W2015016837 hasConceptScore W2015016837C197934379 @default.
• W2015016837 hasConceptScore W2015016837C204787440 @default.
• W2015016837 hasConceptScore W2015016837C27081682 @default.
• W2015016837 hasConceptScore W2015016837C2777350023 @default.
• W2015016837 hasConceptScore W2015016837C2778375690 @default.
• W2015016837 hasConceptScore W2015016837C2778541695 @default.
• W2015016837 hasConceptScore W2015016837C2779631551 @default.
• W2015016837 hasConceptScore W2015016837C2779944601 @default.
• W2015016837 hasConceptScore W2015016837C2780580376 @default.
• W2015016837 hasConceptScore W2015016837C2780590625 @default.
• W2015016837 hasConceptScore W2015016837C2780852908 @default.
• W2015016837 hasConceptScore W2015016837C42219234 @default.
• W2015016837 hasConceptScore W2015016837C71924100 @default.
• W2015016837 hasConceptScore W2015016837C98274493 @default.
• W2015016837 hasIssue "8" @default.
• W2015016837 hasLocation W20150168371 @default.
• W2015016837 hasLocation W20150168372 @default.
• W2015016837 hasOpenAccess W2015016837 @default.
• W2015016837 hasPrimaryLocation W20150168371 @default.
• W2015016837 hasRelatedWork W181586006 @default.
• W2015016837 hasRelatedWork W1966605563 @default.
• W2015016837 hasRelatedWork W1992468542 @default.
• W2015016837 hasRelatedWork W2020802408 @default.
• W2015016837 hasRelatedWork W2029248794 @default.
• W2015016837 hasRelatedWork W2099842030 @default.
• W2015016837 hasRelatedWork W2329765567 @default.
• W2015016837 hasRelatedWork W248248004 @default.

• next